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ABSTRACT
COMPUTER SIMULATION OF CEREBROVASCULAR RESPONSES DURING
INDUCED HYPOTENSION

by
John Schalago

The purpose of this project was to develop a computer model of cerebrovascular
hemodynamics interacting with a pharmacodynamic drug model to examine the effects of
three commonly used anti-hypertensive drugs upon intracranial pressure and cerebral
blood flow. The model is used to predict cerebrovascular response during the
administration of commonly used anti-hypertensive agents.
The mathematical model of intracranial hemodynamics is a seven compartment
constant volume system. A series of resistances relate blood and cerebrospinal fluxes to
pressure gradients between compartments. Arterial, venous and tissues compliance are
included. Autoregulation is modeled by transmural pressure-dependent arterial-arteriolar
resistance. The effects of three drugs (Sodium Nitroprusside, Nitroglycerin and Esmolol)
on cerebrovascular circulation was simulated by a variable arteriolar-capillary resistance
and capillary-venous resistance. The three drugs are known to have a rapid on-set, a
short half-life and are normally therapeutically administered using continuous infusion.
A direct relationship between mean arterial pressure and arteriolar-capillary and
capillary-venous resistance was developed. Comparing the simulation results with
available experimental observations validated the model. The simulation program was
written usingVisSim

® dynamic simulation language for an IBM-compatible PC.

The developed model was used to calculate intracranial pressure changes that
occur with deliberate hypertension. Response to intravascular administration was
predicted for simulated patients with elevated intracranial pressure and non-autoregulated
cerebral circulation. The simulations demonstrated that Sodium Nitroprusside and
Nitroglycerin reduce mean arterial pressure while simultaneously elevating intracranial
pressure. The simulations demonstrated that intracranial pressure increases with
reduction in mean arterial pressure until a maximum value is reached at which point a
reduction in intracranial pressure occurs with additional decreases in mean arterial
pressure. Esmolol reduces mean arterial pressure without a significant change in
intracranial pressure.
The presented simulation compared the effect of commonly used antihypertensive drugs on cerebral hemodynamics. The simulation demonstrates that
Sodium Nitroprusside and Nitroglycerin may increase intracranial pressure. This effect is
more significant in non-autoregulated circulation. Only minor intracranial pressure
changes have been predicted during Esmolol infusion. Esmolol is a preferable intraoperative hypotensive agent for patients with non-auto-regulated cerebral circulation
(head trauma, brain tumor, etc.) The model developed in this project can be extended to
analyze more complex intraoperative events by adding new submodels.
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CHAPTER 1
INTRODUCTION

1.1 Overview of Induced Hypotension
Multiple factors combine to maintain normal systemic pressure. These factors include
cardiac output, circulating blood volume, the peripheral resistance, blood viscosity and
compliance of large vessels. Further, these factors are influenced and subject to control
by numerous physiological factors such as the central nervous system, and hormones.
Deliberate hypotension is an anesthetic technique used in a variety of surgical techniques
to improve the surgical field, reduce blood loss, and reduce transfusion requirements [12]. The factors of most importance during deliberate hypotension are peripheral
resistance, cardiac output and total circulating blood volume. When total blood volume
is maintained constant, deliberate hypotension is induced by reducing cardiac output
and/or decreasing peripheral resistance. Today, deliberate hypotension is induced
intraoperatively through the administration of anti-hypertensive (hypotensive) agents [1].
These agents induce hypotension by dilating peripheral vessels or by reducing cardiac
output [2].
The cerebral circulatory system is a constant volume system consisting of blood,
cerebrospinal fluid and cerebral tissue. Complex multiple factors combine to maintain
normal cerebral spinal fluid levels, cerebral blood flow (CBF), and intracranial pressure
(ICP). Cerebral blood volumes are distributed between arteries, capillaries and veins,
with the greatest volume (75%) in the veins. Administration of anti-hypertensive agents
during induced hypotension are often associated with untoward events such as increased
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intracranial pressure and increased cerebral blood flow depending on patient status [23].
Specifically, vasodilators are anti-hypertensive agents that reduce systemic pressure by
dilating peripheral vessels and directly dilate the cerebral capacitance vessels increasing
cerebral blood volume [18]. The increased cerebral blood volume may concomitantly
increase intracranial pressure. In addition, in normal patients, autoregulatory response to
decreased mean arterial pressure causes an increase in cerebral blood flow.
The complexity of the cerebral circulatory system and autoregulation make it
difficult to predict the unanticipated complications and changes in intracranial pressure
and cerebral blood flow during deliberate hypotension. Computer simulation may be a
useful tool to access the complex interactions of the numerous hemodynamic variables
affecting intracranial hemodynamics.

1.2 Intracranial Hemodynamic Models
Over the past fifteen years, various biophysical and mathematical models have been
developed to simulate intracranial hemodynamics [5-12]. Hudetz, et. al., developed a
computer model of cerebral circulation to predicted changes in cerebral blood flow and
tissue oxygenation with autoregulation intact during occlusion of the middle cerebral
artery (MCA) [8]. The model design included the pial and intracerebral arteries and
autoregulatory system. Several models have been developed to evaluate cerebrospinal
fluid dynamics [3, 4, 7, 9]. These models were designed using known experimental data
and were used to predict the effect of dynamic changes in cerebrospinal fluid on
cerebrospinal fluid pressure. Sorek designed a lumped parameter compartmental model
of the cerebrovascular system [5]. The model was used to predict changes in resistance
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and compliance during non-steady cerebrospinal fluid flow. The model developed by
Kadas, et.al., was a four compartmental model of intracranial hemodynamics [3]. The
model was used to predict cerebral autoregulatory induced changes in cerebral blood
flow. Hoffman designed a mathematical model to predict changes in intracranial
cerebrospinal fluid and intracranial hemodynamics [15]. The model includes cerebral
circulatory and systemic circulatory components. This model was used to predict
cerebral circulatory response to changes in mean arterial pressure.
The most extensive and complete model was developed by Ursino [10-12]. The
model was designed to simulate the behavior of the intracranial arterial vascular bed, the
intracranial venous vascular bed, cerebrospinal fluid absorption and production process
and incorporates physiological and anatomical data. The model is a lumped parameter
seven-compartment, constant volume system. The seven compartments represent
cerebrovascular arterial and arteriolar beds, an intracranial capillary compartment, a
venous vascular bed, venous sinuses, a cerebrospinal fluid compartment (brain tissue)
and a central venous compartment. The unique aspect of the model is the inclusion of
cerebral blood flow autoregulation, and cerebrospinal fluid formation. In addition, the
model calculates model parameters using physiological and recent anatomical data.
Bekker, etal., recently reported the use of a model to predict changes in intracranial
hemodynamics during administration of an anesthetic drug [31]. Specifically, the model
consisted of a sub-model designed to simulate the pharmacokinetic and pharmacological
effect of thiopental and a modified version of the intracranial hemodynamic model
developed by Ursino.
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1.3 Objective
During induced hypotension, the complex interaction of numerous hemodynamic
variables affecting intracranial hemodynamics makes it difficult to predict changes in
intracranial pressure and cerebral blood flow. A computer model consisting of a
cerebrovascular hemodynamic subsystem interacting with a pharmacodynamic drug
model may be a useful tool capable of predicting simulated patient response with varying
physiological conditions.
The objectives of this research project are:
1. To develop a computer model of cerebrovascular hemodynamics
interacting with a pharamcodynamic drug model to examine the
cerebrovascular response during induced hypotension.
2. Predict the cerebrovascular response to three commonly used antihypertensive agents, two vasodilators and a beta-adrenergic.
3. Use the computed data to recommend an intraoperative hypotensive agent
depending on patient status.

CHAPTER 2
MODEL

2.1 Overview
The overall structure of the three system models developed to simulate and predict the
effects of three commonly used anti-hypertensive agents are presented in figures 1, 2, and
3. Each computer model consists of a sub-model of pharmacodynamic effects of a
particular anti-hypertensive agent interfaced with a modified version of the intracranial
hemodynamic model first developed by Ursino.
The intracranial hemodynamic sub-model is a lumped parameter seven-compartment
constant volume system. The seven compartments represent cerebrovascular arterial and
arteriolar beds, intracranial capillary compartment, venous vascular bed, venous sinuses,
cerebrospinal fluid compartment (brain tissue) and a central venous compartment. The
unique aspect of the model is the inclusion of cerebral blood flow autoregulation,
cerebrospinal fluid formation and calculation of model parameters using physiological
and recent anatomical data.
The three pharmacodynamic sub-models were developed from experimental data [1330]. The pharmacodynamic sub-model for sodium nitroprusside was constructed with the
assumption that sodium nitroprusside predominantly affects cerebral arteriolar-capillary
vessels [14-19]. The sub-model is defined by an exponential relationship between the
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conductance of the arteriolar-capillary bed and the percent change in mean arterial
pressure during sodium nitroprusside induced hypotension.
The pharmacodynamic sub-model for nitroglycerin was constructed assuming that
nitroglycerin predominantly affects cerebral venous vessels [20-25]. The sub-model is
defined by an exponential relationship between conductance of the venous bed and
percent change in mean arterial pressure during nitroglycerin induced hypotension. The
pharmacodynamic sub-model for esmolol differs from the other sub-models in that we
assume that esmolol effects mean arterial pressure without concomitant effect on
cerebrovascular vessels [26-30]. The sub-model is an described by an exponential
relationship between change in mean arterial pressure and drug concentration.

2.2 Intracranial Hemodynamic Model
The model of intracranial hemodynamics was chosen as the cerebral circulation
submodel because the model includes cerebrospinal fluid formation rate as a function of
transmural pressure, capable of simulating hemodynamic response with autoregulation
intact and non-autoregulated conditions, and the system parameters and constants are
based upon physiological and anatomical data [10-12]. The equations and system
parameters that define the cerebral circulation model are provided in the Appendix. An
overview of the sub-model design and the general principles and equations are described
herein. In addition, the subsystem for each of the three anti-hypertensive agents
investigated in this paper is described in detail.
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The following assumptions were made to derive the cerebral circulatory system and
pharmacodynamic model equations:
•

The change in fluid in a compartment is equal to the sum of the net fluid
influx through the compartmental boundaries, plus external sources.

•

The change in volume is produced by the changes in pressure difference.

•

Arteriolar-capillary and venous cerebrovascular resistance is controlled by
chemical factors including pharmacological agents.

•

The sum of all volumes does not change in time, i.e., constant volume.

•

Arterial-arteriolar and venous cerebrovascular resistance is a function of
transmural pressure.

The mathematical model of intracranial hemodynamics is a seven-compartment
constant volume system. The seven compartments represent cerebrovascular arterial and
arteriolar beds, intracranial capillary compartment, venous vascular bed, venous sinuses,
cerebrospinal fluid compartment (brain tissue) and a central venous compartment.
The behavior of each compartment is represented by a single pressure value and CSF
fluxes to the pressure gradient between compartments:

where V17 is the volume of compartment n surrounded by m compartments, q,„, denotes
the flux between compartments in and 17, (P„, - P,,) is the pressure difference between the
n-th and m-th compartment, and

is the resistance of the compartmental boundary.

As described above a unique feature of the model is the incorporation of cerebrospinal
fluid production and absorption processes.

The CSF production rate is directly
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proportional to the difference between capillary and intracranial pressures and inversely
proportional to the resistance that the choroid plexus applies to CSF secretion. The CSF
absorption rate is directly proportional to the difference between intracranial and dural
sinus pressures and inversely proportional to the arachoid villi resistance to fluid flow.
Two lumped parameters are used to describe changes in cerebral arterial and venous
blood volumes. The relationship between arterial blood volume and pressure is assumed
to be monoexponential and is described by the following equation
(k=iPa-(V2ce0))
where V a o, and Ka are constants. Compliance of the arterial compartment is defined by
the equation
Ca=dVa/d(Pa-Pic)=1/Ka(Pa-Pic)

(3)

where C a is the arterial compartment compliance, Ka denotes the arterial elastance coefficient
and pressure in the arterial, and intracranial compartments are described by P a and P ic . The
relationship between venous blood volume and pressure is also assumed to be
monoexponential and is described by the following equation
(v+K=iPV4-c0e)
where Va0 , and Kv are constants. Compliance of the venous compartment is defined by
the equation
Ca=dVa/d(Pa=Pic)=1/Ka(Pa-Pic-Pvi) (5)
where Cv is the venous compartment, Kv denotes the venous elastance coefficient and
pressure in the venous compartment, and intracranial tissue are described by P v , P ic
Parameter Pvi represents the transmural pressure value at which the large cerebral vessels
collapse and therefore, venous compliance would become infinite.
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An exponential pressure-volume relationship is also assumed for the cerebral tissue
compartment. The cerebral tissue compliance is equal to the negative of the change in
volume of the tissue compartment divided by the change in pressure which is inversely
proportional to the product of intracranial pressure and the elastance coefficient, that is
Cic=-(dVic-dPic) =1 / Ke [Pic+( Pic/ P01)]2(6)

Rearranging, the compliance of cerebral tissue is described by
Cic= 1/[Ke* (Pic+ (Pic / P

ic)2)]

(7)

where K denotes elastance coefficient of cerebral tissue, P 01 is a constant and Piv,
represents intracranial pressure. The equations indicate that at low intracranial pressure
the cerebral tissue compliance is linear because the quadratic term becomes negligible.
Conversely, when intracranial pressure rises the quadratic term becomes significant and
cerebral tissue compliance decreases, i.e., the compartment becomes more rigid.
The differential equations describing intracranial dynamics are written by imposing a
mass balance on each compartment. The general equation for describing intracranial
dynamics follows:

where C m,n (P m, P n) is the pressure dependent compliance of the nth compartment. The
equation states that the flux into the n-th compartment is equal to the flux out of the n- th
compartment. Accumulation within the n- th compartment is assumed to be zero.
The intracranial volume is a function of arterial and venous blood volume, cerebrospinal
fluid volume, and cerebral volume. Since the model is a constant volume, the constancy
of the total intracranial volume, in keeping with the Monro-Kelly principle, is expressed
by the following equation:
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n=0(ΣdV9/t+)Q
Where Q denotes the rate at which the CSF compartment can expand. This equation may
be used to simulate the injection of fluid into the CSF space as well as pathologic
conditions [11].
Cerebral autoregulation is represented by a table function of arterial-arteriolar
conductances versus transmural pressures across the arterial wall. The autoregulatory
curve generated from the data set correlates well with experimentally observed changes
in autoregulatory resistance. During the computational simulation the program selects a
conductance corresponding to the transmural pressure at the given time. Inhibition of the
autoregulation response is simulated by setting arterial-arteriolar conductance to a fixed
value of (100 mm Hg)-1 .

2.3 Overview of Pharmacodynamic Models
The effect of three antihypertensive agents (sodium nitroprusside, nitroglycerin, and
esmolol) on cerebral circulation is simulated by a variable-arteriolar-capillary resistance
relationship, a venous resistance relationship, and a drug concentration mean arterial
pressure relationship. These three agents are known to have a rapid onset, a short halflife and are normally therapeutically administered using a continuous infusion rate.
Sodium nitroprusside and nitroglycerin are vasodilators which means that mean arterial
pressure is reduced by dilatation of peripheral vessels, including cerebral vascular
vessels. Esmolol is a beta-adrenergic blocker. Beta-adrenergic blockers reduce systemic
pressure primarily by reducing cardiac output.
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Sodium nitroprusside is predominantly an arterial dilator that directly dilates the
cerebral arteriolar-capillary bed [14]. The effect of sodium nitroprusside was simulated
by a mean arterial pressure dependent arteriolar-capillary resistance relationship. This
resistance is the predominant site of sodium nitroprusside action in the brain. In the
model, the resistance of the arteriolar-capillary compartment is a function of a constant,
G„. This resistance, G„, is not controlled by autoregulation, but rather G ar ., responds
to secondary effects such as carbon dioxide concentration, metabolic changes and drug
administration.
The model was used to determine G„„ values by inputting a constant mean arterial
pressure and varying G,„ until the simulated change in intracranial pressure correlated
with experimental data [14-19]. The percent change in mean arterial pressure,
intracranial pressure, cerebral blood flow, and G ar „ values were recorded.
The calculated conductance values were regressed using the exponential equation:

where x is the percent change in mean arterial pressure induced by the administration of
sodium nitroprusside. During model simulation, percent change in mean arterial
pressure, variable x, is input into the pharmacodynamic model and the corresponding
conductance value is determined. . Figure 1 shows the sodium nitroprusside sub-model
interfacing with the intracranial hemodynamic model.
Nitroglycerin is predominantly a venodilator that directly dilates the cerebral venous
bed [25]. The effect of nitroglycerin was simulated by a mean arterial pressure
dependent venous vascular resistance relationship. This resistance is the only site of
nitroglycerin action in the brain.
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Figure 1 Overall structure of the model, the affected site P a , P ar = arterial and arteriolar
pressures; P c , P v = capillary and cerebral venous pressures; P vs = venous sinus pressure;
Pcv = central venous pressure; Caf, Cvf = cerebral arterial and venous compliances; C f
brain tissue compliance; Cve = extracranial venous compliance; R aar = variable arterialarteriolar resistance (transmural pressure-dependent); R an: = arteriolar-capillary resistance
(thiopental concentration dependent); R ev, Rvvs = capillary-venous system-venous sinuses
resistance; Ref, R fvs = resistance to cerebrospinal fluid formation and cerebrospinal fluid
outflow; Rvsce = resistance to the extracranial venous outflow.

Figure 2: Overall structure of the model. Pa , Par= arterial and arteriolar pressures; Pc , Pv
= capillary and cerebral venous pressures; the affected site Pvs = venous sinus pressure;
Pcv = central venous pressure; C af, C vf = cerebral arterial and venous compliances; Cf =
brain tissue compliance; C ve = extracranial venous compliance; Raar = variable arterialarteriolar resistance (transmural pressure-dependent); R arc = arteriolar-capillary resistance
(thiopental concentration dependent); R ev, Rvvs = capillary-venous system-venous sinuses
resistance; Ref, Rfvs, = resistance to cerebrospinal fluid formation and cerebrospinal fluid
outflow; Rvsce = resistance to the extracranial venous outflow.
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Figure 3: Overall structure of the model of Esmolol. Pa , Par = arterial and arteriolar
pressures; Pc , Pv = capillary and cerebral venous pressures; P vs = venous sinus pressure;
Pcv = central venous pressure; Caf, C v f = cerebral arterial and venous compliances; C f =
brain tissue compliance; C ve = extracranial venous compliance; R aar = variable arterialarteriolar resistance (transmural pressure-dependent); Raa,rteiolr-c=pcysne
(thiopental concentration dependent); R ev, Rvvs = capillary-venous system-venous sinuses
resistance; Ref, Rfvs = resistance to cerebrospinal fluid formation and cerebrospinal fluid
outflow; Rvsce = resistance to the extracranial venous outflow.
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In the model, the resistance of the venous compartment is determined by the resistance
constant, G
ce . This resistance, Gce, is not controlled by autoregulation, but rather Gce
Gce
responds to secondary effects such as carbon dioxide concentration, metabolic changes
and drug administration. The model was used to determine
constant mean arterial pressure and varying

values by inputting a

until the simulated change in intracranial

pressure correlated with the published experimental ICP [20-25]. The percent change in
mean arterial pressure, intracranial pressure, cerebral blood flow, and Gar-c values were
recorded.
The calculated conductance values were regressed using an exponential equation:

where x is a percent change in mean arterial pressure induced by the administration of
nitroglycerin. During model simulation, percent change in mean arterial pressure,
variable x, is input into the pharmacodynamic model and the corresponding conductance
value is determined. Figure 2 shows the nitroglycerin pharmacodynamic sub-model
interfacing with the intracranial hemodynamic model.
Esmolol directly affects systemic pressure by changing cardiac output and without
effecting cerebral vessels [25-29]. The effect of esmolol on cerebrovascular circulation
was simulated by a drug concentration dependent change in mean arterial pressure.
Experimental data (drug concentration and mean arterial pressure) from several
investigations studying the cardiovascular effects of esmolol were regressed to develop a
relationship between esmolol drug concentration and mean arterial pressure [25-29]. The
equation is presented below.

MAP(%change)=100.0*exp(-x/9.167)

(12)
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During model simulation, drug concentration, variable x, is input into the
pharmacodynamic model and the percent change in mean arterial pressure is simulated.

2.4 Operation of the Computer Model
The simulation program was written in VisSim®, a simulation programming language for
an IBM compatible PC. VisSim® is a Windows-based modeling program designed for
programming simulations of complex dynamic systems, such as the cerebrovascular
hemodynamic model described herein. In VisSim ® , models are constructed in the form
of block diagrams from function blocks and connecting wires. Each interconnected block
represents and describes a portion of the system, e.g., linear and nonlinear equations.
Fourth-order Runge-Kutta integration blocks with a time interval of 50 msec were chosen
for a solution of the model equations. A 50 msec time interval was chosen to provide
optimal performance and precision. A larger time interval would decrease simulation
time but reduce system precision, while smaller time intervals significantly increase
simulation time without increasing system precision. A 32-bit PC microcomputer was
used to realize real-time simulation. The Vissim ® code is provided in Appendix B.

CHAPTER 3
RESULTS

The computer model developed was used to calculate intracranial pressure (ICP) and
cerebral blow flow (CBF) changes that occur with deliberate induced hypotension.
Simulation results include computation of ICP and CBF as a function of mean arterial
pressure (MAP) with autoregulation intact and autoregulation impaired. In addition,
cerebrovascular response was predicted for simulated patients with normal blood pressure
(100 mm Hg) and increased blood pressure (150 mm Hg). The computed predictions
were evaluated and the preferable intra-operative hypotensive agent was proposed.

3.1 Clinical Applications
The anti-hypertensive agents evaluated and discussed herein are known to have a rapid
on-set and are typically administered using a constant infusion. Although these agents
may be administered intraoperatively as a bolus to cause an immediate, rapid decrease in
mean arterial pressure, for the purposes of this project cerebrovascular response is
simulated assuming a constant infusion rate. For simulated response to sodium
nitroprusside and nitroglycerin, the percent change in mean arterial pressure is varied.
For esmolol, drug concentration is varied inducing a corresponding percent change in
mean arterial pressure. The model predicted changes intracranial pressure and cerebral
blood flow are recorded for each agent.
The computer simulation data are plots of changes in intracranial pressure and
cerebral blood flow versus the percent change in mean arterial pressure. The plots can be
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used to predict intracranial pressure and cerebral blood changes at a corresponding
change in mean arterial pressure for each agent.
Standard clinical practice is to vary the infusion rate and/or drug concentration until
the desire reduction in mean arterial blood pressure is achieved. The patient status is
monitored for untoward changes and agent administration is adjusted accordingly. Thus,
we have chosen the data plot technique described above to provide clinically relevant and
useful simulated data.

3.2 Vasodilators: Sodium Nitroprusside
ICP and CBF changes during induced hypotension were computed for initial ICP values
of 10, 30, and 50 mm Hg and mean arterial pressure of 150 mm Hg, simulating a
hypertensive state, and 100 mm Hg, simulating a normal blood pressure. Induced
hypotension was simulated as a percent reduction in mean arterial pressure from a ten
percent (10%) reduction in mean arterial pressure to a forty percent (40%) reduction in
mean arterial pressure.
Figure 4 simulated data plot shows that intracranial pressure increases during induced
hypotension until a maximum pressure is reached, further reduction in mean arterial
pressure reduces intracranial pressure. For an initial intracranial pressure of 10 mm Hg,
intracranial pressure increases approximately (80%) of baseline at a (35%) reduction in
mean arterial pressure. At higher initial intracranial pressures, 30 mm Hg and 50 mm Hg,
the percent change in intracranial pressure is less, approximately thirty percent (30 %)
and (10 %) respectively, than the percent ICP change observed at an initial ICP of 10
mmHg. Similarly, Figure 5 simulated data plot shows that a simulated hypertensive
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patient with increased intracranial pressure will experienced marked increase in
intracranial pressure. A simulated patient with an initial intracranial pressure of 30 mm
Hg will experience approximately one hundred percent (100%) increase in ICP from
baseline at a thirty percent (30%) reduction in mean arterial pressure. In addition, a
simulated patient with an initial intracranial pressure of 50 mmHg will experience a sixty
percent (60%) increase in intracranial pressure at a twenty percent (20 %) reduction in
mean arterial pressure. Conversely, a hypertensive simulated patient with normal
intracranial pressure (ICP = 10 mmHg) will experience only a fifty percent (50%)
increasse at a forty percent (40%) reduction in mean arterial pressure.
Summarizing, the simulated results in figures 4 and 5 show that in simulated patients
with autoregulation intact the administration of sodium nitroprusside, a vasodilator,
induces hypotensive state and increases intracranial pressure. Direct dilation of the
cerebral arterial vascular bed increase the cerebral blood volume therein with
concomitant increased in ICP. This is consistent with observations of Cottrell, et a/, who
reported marked increases (200% of baseline) in intracranial pressure during the
administration of sodium nitroprusside [19].
In addition, figures 4 and 5 show that at higher initial intracranial pressure the onset
of increased intracranial pressure occurs with approximately five percent (5%) reduction
in mean arterial pressure. Intracranial pressure maximum is achieved at approximately
fifteen percent (15%) reduction in mean arterial pressure. Further reduction in mean
arterial pressure reduces ICP and the most pronounced change in intracranial pressure
occurs at an initial intracranial pressure of 30 mm Hg. At normal intracranial pressure
(ICP=10 mm), intracranial pressure maximum is reached at a thirty percent (30%)
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reduction in mean arterial pressure. The shape of the curve infers a linear relationship
between percent change in mean arterial pressure and ICP similar to the clinical results
reported by Cottrell who reported a linear relationship between ICP and percent change
in blood pressure in patients with space occupying lesions.
Figures 6 and 7 show predicted changes in intracranial pressure computed by the
simulation model during administration of sodium nitroprusside in a patient without
autoregulation. A comparison of the predicted responses in simulated patients with
autoregulation intact and with autoregulation impaired show that the change in
intracranial pressure is more pronounced in a patient with autoregulation intact. Further,
a patient with autoregulation impaired and normal intracranial pressure (ICP=10 mm Hg)
will not experience the marked increase in intracranial pressure observed in the patient
with autoregulation intact.
The results show that in simulated patients with autoregulation intact, the
autoregulatory response may increase CBF in response to a reduction in mean arterial
pressure increasing cerebral blood volume within the now more compliant compartment.
In addition, computed intracranial pressure changes for a patient with autoregulation
impaired shows that intracranial pressure is not significantly affected by a reduction in
mean arterial pressure.
A plot of cerebral blood pressure versus percent change mean arterial pressure,
(figure 8), shows that sodium nitroprusside does not significantly affect cerebral blood
flow. These results are consistent with the reported experimental data that indicate that
CBF is preserved during administration of sodium nitroprusside [15-18].
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Sodium Nitroprusside Administration in a Simulation Patient with Autoregulation
Intact and MAP = 100 mm Hg

Figure 4: Effects of the administration of sodium nitroprusside on intracranial pressure in
a simulated patient with autoregulatory system intact and an initial mean arterial pressure
of 100 mm Hg.
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Sodium Nitroprusside Administration in Simulated Patient with Autoregulation
Intact and MAP = 150 mm Hg

Figure 5: Effects of the administration of sodium nitroprusside on intracranial pressure in
a simulated patient with autoregulatory system intact and an initial mean arterial pressure
of 150 mm Hg.
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Sodium Nitroprusside Administration in Simulated Patients with Autoregulation
Impaired and MAP = 100 mm Hg

Figure 6: Effects of the administration of sodium nitroprusside on intracranial pressure
in a simulated patient with autoregulatory system impaired and an initial mean arterial
pressure of 100 mm Hg.

?-4

Sodium Nitropruside Administration in Simulated Patients with Autoregulation
Impaired and MAP = 150 mm Hg

Figure 7: Effects of the administration of sodium nitroprusside on intracranial pressure
in a simulated patient with autoregulatory system impaired and an initial mean arterial
pressure of 150 mm Hg.
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Sodium Nitroprusside Administration in a Simulated Patient with Autoregulation
Intact and MAP = 100 mm Hg

Figure 8: Effects of the administration of sodium nitroprusside on cerebral blood flow in
a simulated patient with autoregulatory system intact and an initial mean arterial pressure
of 100 mm Hg.
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3.3 Vasodilators: Nitroglycerin
The effect of nitroglycerin, a venodilator, was simulated under the same conditions as the
sodium nitroprusside model. ICP and CBF changes during induced hypotension were
computed for initial ICP values of 10, 30, and 50 mm Hg and mean arterial pressure of
150 mm Hg, simulating hypertension, and 100 mm Hg, simulating normal blood
pressure. Induced hypotension was simulated as a percent reduction in mean arterial
pressure from a ten percent (10%) reduction to forty percent (40%) reduction.
Figures 9 and 10 show that administration of nitroglycerin to a simulated patient
with autoregulation intact with normal or elevated intracranial pressure results in a
marked increase in intracranial pressure in a simulated patients with normal initial
intracranial pressure (10 mm Hg) at an induced hypotension of twenty percent reduction
of mean arterial pressure and greater. The model predicts that dilation of the intracranial
venous capacitance vessels increases the cerebral blood volume concomitantly increasing
intracranial pressure. This is consistent with in-vivo observations presented elsewhere
[20-25]. Further, Lagerkranser demonstrated an exponential relationship between
intracranial pressure and intracranial volume [22].
Conversely, figures 9 and 10 show that simulated patients with elevated initial
intracranial pressure (ICP equal to 30 mmHg and 50 mmHg) will experience a reduction
in intracranial pressure. The intracranial pressure of a simulated patient with normal
mean arterial pressure and an initial intracranial pressure of 30 mmHg decreases by
approximately ten percent (10 %) at a forty percent (40%) reduction in mean arterial
pressure. Similarly, the intracranial pressure of a simulated patient with normal mean
arterial pressure and an initial intracranial pressure of 50 mmHg decreases by
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approximately forty percent (40%) at a forty percent (40%) reduction in mean arterial
pressure, respectively.
Figures 11 and 12 demonstrate that in simulated patients with autoregulation impaired
the most pronounced change occurs at a normal initial intracranial pressure of 10 mm Hg.
Further, the computer model predicts that direct dilation of cerebral venous vascular bed
and reduced mean arterial pressure in a simulated hypertensive patient and a normal
patient at increased intracranial pressure (30 mmHg and 50 mmHg) reduces intracranial
pressure. These results indicate that at high intracranial pressure and low cerebral blood
flow a significant reduction in mean arterial pressure and venodilation slightly decreases
intracranial volume.
The model predicts that cerebral blood flow is directly related to intracranial pressure
and mean arterial pressure. Figure 13 shows that cerebral blood flow during the
administration of nitroglycerin varies within five percent of baseline until a twenty
percent (20%) reduction in mean arterial pressure is achieved. Cerebral blood flow will
then decrease with increased reduction in mean arterial pressure and increased
intracranial pressure. These results are consistent with animal studies conducted by
Traystman to evaluate the effect nitroglycerin on cerebral blood flow and cerebral spinal
fluid [25].
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Nitroglycerin Administration in a Simulated Patient with Autoregulation Intact
and MAP = 100 mm Hg

Figure 9: Effects of the administration of nitroglycerin on intracranial pressure in a
simulated patient with autoregulatory system intact and an initial mean arterial pressure
of 100 mm Hg.
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Nitroglycerin Administration in a Simulated Patient with Autoregulation Intact
and MAP = 150 mm Hg
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Figure 10: Effects of the administration of nitroglycerin on intracranial pressure in a
simulated patient with autoregulatory system intact and an initial mean arterial pressure
of 150 mm Hg.
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Nitroglycerin Administration in a Simulated Patient with Autoregulation Impaired
and MAP = 100 mm Hg
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Figure 11: Effects of the administration of nitroglycerin on intracranial pressure in a
simulated patient with autoregulatory system impaired and an initial mean arterial
pressure of 100 mm Hg.
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Nitroglycerin Administration in Simulated Patients with Autoregulation Impaired
and MAP = 150

Figure 12: Effects of the administration of nitroglycerin on intracranial pressure in a
simulated patient with autoregulatory system impaired and an initial mean arterial
pressure of 150 mm Hg.

Nitroglycerin Administration in a Simulated Patient with Autoregulation
Intact and MAP = 100 mm
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Figure 13: Effects of the administration of nitroglycerin on cerebral blood flow in a
simulated patient with autoregulatory system intact and an initial mean arterial pressure
of 100 mm Hg.
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3.4 Beta-adrenergic Blockers: Esmolol
Similar to sodium nitroprusside and nitroglycerin, esmolol has a rapid onset, short halflife and is typically administered using a constant infusion rate. These hypotensive
agents differ in that esmolol reduces mean arterial pressure by reducing cardiac output
and does not dilate cerebral vessels whereas vasodilators such as sodium nitroprusside
and nitroglycerin dilate cerebral vessels concurrent with dilatation of systemic vessels.
Assuming a constant infusion rate, ICP and CBF changes during induced hypotension
were computed for initial ICP values of 10, 30, and 50 mm Hg and mean arterial pressure
of 150 mm Hg, simulating hypertension, and 100 mm Hg, simulating normal blood
pressure. Induced hypotension was simulated as a percent reduction in mean arterial
pressure from a ten percent (10%) reduction to forty percent (40%) reduction.
Figures 14, and 15 show that administration of esmolol in simulation patients with
autoregulation intact and initial intracranial pressure of 10 mm Hg does not significantly
affect intracranial pressure. In a simulated normal patient with an initial intracranial
pressure of 30 mmHg, intracranial pressure is preserved until a twenty percent reduction
in mean arterial pressure is achieved; further reduction in mean arterial pressure reduces
intracranial pressure. In a simulated hypertensive patient with initial intracranial pressure
of 30 mmHg, intracranial pressure is preserved from ten percent to forty percent
reductions in mean arterial pressure. These predicted results are consistent with clinically
observed responses reported elsewhere [26-30]. In addition, Ornstein, et.al.,evalutd
the effects of esmolol on intracranial pressure and mean arterial pressure during resection
of intracranial arteriovenous malformation (AVM) and reported that esmolol rapidly
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induces a twenty percent reduction in mean arterial pressure without causing large
fluctuations in intracranial pressure [27].
Figure 18 shows that induced hypotension in simulated patients with elevated
intracranial pressure reduces cerebral blood flow. Simulated patient with normal
intracranial pressure will experience negligible changes in cerebral blood flow.
A comparison of computed response in simulated patients with autoregulation intact
and autoregulation impaired demonstrates that both populations will experience similar
changes in intracranial pressure and cerebral blood flow. Reference figures 16 and 17 for
predicted cerebral vascular response in simulated patients with autoregulation impaired.

Esmolol Administration in a Simulated Patient with
Autoregulation Intact and Initial MAP = 100 mm

Figure 1 4: Effects of the administration of esmolol on intracranial pressure in a simulated
patient with autoregulatory system intact and an initial mean arterial pressure of 100 mm
Hg.
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Esmolol Administration in Simulated Patient with Autoregulation
Intact and MAP = 150 mm Hg

Figure 15: Effects of the administration of esmolol on intracranial pressure in a
simulated patient with autoregulatory system intact and an initial mean arterial pressure
of 150 mm Hg.
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Esmolol Adminisration in a Simulated Patient with Auregulation
Impaired and MAP = 100 mm Hg

Figure 16:

Effects of the administration of esmolol on intracranial pressure in a
simulated patient with autoregulatory system impaired and an initial mean arterial
pressure of 100 mm Hg.
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Esmolol Administration in Simulated Patients with Autoregulation
Impaired and MAP = 150 mm Hg

Percent Decrease in MAP

Figure 17: Effects of the administration of esmolol on intracranial pressure in a
simulated patient with autoregulatory system impaired and an initial mean arterial
pressure of 150 mm Hg.
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Esmolol Administration in a Simulated Patient with Autoregulation
Intact and MAP = 100 mm Hg

0

10

20

30

40

Percent Decrease in MAP

Figure 18: Effects of the administration of esmolol on cerebral blood flow in a simulated
patient with autoregulatory system intact and an initial mean arterial pressure of 100 mm
Hg.

CHAPTER 4
DISCUSSION

A variety of hypotensive techniques and anti-hypertensive agents are used to reduce
neurosurgical blood loss and maintain a dry surgical field. Sodium nitroprusside is the
most commonly used as a hypotensive agent in neurosurgery for the provision of
deliberate hypotension. The prevalent use of the agent for this indication is in part
attributed to its rapid onset and ease of administration. Sodium nitroprusside is a
vasodilator that predominantly dilates arteriolar-capillary vessels. Further, clinical data
in animal and human studies shows that administration of sodium nitroprusside decreases
cerebral vascular resistance increasing cerebral blood volume concomitantly increasing
intracranial pressure [15-20].
Another commonly used nitrovasodilator is nitroglycerin. Nitroglycerin has gained
popularity over the past twenty years because of its similar characteristics to sodium
nitroprusside. This agent has a rapid onset, easy to manage and reduces blood pressure
by direct dilation of vascular vessels. In addition, nitroglycerin dilates the venous
cerebral vascular bed increasing intracranial capacitance. Clinical data has shown that
direct dilation of the venous vascular bed may concomitantly increase intracranial
pressure in response to increased cerebral blood volume. This cerebrovascular result has
been demonstrated in animal studies on dogs and baboons and in controlled clinical trials
on human subjects [20-25].
Esmolol, a beta-adrenergic blocker, is an anti-hypertensive agent commonly used to
induce hypotension in patients with intracranial arteriovenous malformations. Beta-
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adrenergic blockers reduce mean arterial pressure by reducing cardiac output. Unlike
vasodilators, these agents do not affect the capacitance of cerebral vessels.
Our computer simulations demonstrate that esmolol may be the preferable
hypotensive agent. Esmolol does not significantly affect cerebral blood flow or
intracranial pressure regardless of the initial simulated patient status. In both simulated
patients with autoregulation intact and autoregulation impaired with normal and increased
intracranial pressure, cerebral blood flow is preserved and no marked increase in
intracranial pressure is observed. These results are consistent with reported
cerebrovascular response in animal studies and controlled human studies [26-30]
Sodium nitroprusside causes marked increase in intracranial pressure in simulated
patients with autoregulation intact. These effects may be attributed to two basic
mechanisms: direct dilation of the cerebral arterial vessels and autoregulatory response to
changes in mean arterial pressure. Direct dilation of cerebral arterial vessels increases the
cerebral blood volume with concomitant increase in ICP. Further, a concurrent increase
in cerebral blow flow was induced by the system simulated autoregulatory response to
reduction in mean arterial pressure.
Computations of cerebrovascular response to the administration of sodium
nitroprusside in simulated patients with autoregulation impaired demonstrate that
intracranial pressure is maintained with increased reduction in mean arterial pressure.
These effects may be attributed to changes in mean arterial pressure during impaired
autoregulation and direct dilation of cerebral arterial vessels. Reduction of mean arterial
pressure in a simulated patient with autoregulation impaired significantly decreases
cerebral blood flow. These results indicate that the reduction in mean arterial pressure
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and cerebral blood flow negate the effect arterial vessel dilation and increased
capacitance of the compartment. Unlike the simulated patient with autoregulation intact
that shows an increase in cerebral blood volume, the cerebral blood volume in the
simulated patient with autoregulation impaired is maintained.
The computer model developed to determine cerebrovascular hemodynamic response
to the administration of nitroglycerin demonstrated comparable results to sodium
nitroprusside in simulated patients with autoregulation intact. Computation shows that
the administration of nitroglycerin may cause marked increases in intracranial pressure
while maintaining cerebral blood flow. These effects are attributed to two basic
mechanisms: direct venodilation and reduction in systemic mean arterial pressure.
Dilation of the intracranial venous capacitance vessels increases the cerebral blood
volume concomitantly increasing intracranial pressure. In simulated patients with
autoregulation impaired, computations show that intracranial pressure and cerebral blood
flow decrease.
The computed results in simulated patients with autoregulation impaired during the
administration of sodium nitroprusside may expose a limitation of the computer model.
The presence of intracranial mass lesions inhibits the autoregulatory system, directly
affecting cerebral vascular compliance and may block outflow [19, 20, 27]. The clinical
data obtained in these patients indicate that at increased initial intracranial pressure direct
dilation of cerebral arterial vessels and the presence of intracranial lesions cause a
marked increase in intracranial pressure. Therefore, the computed data for sodium
nitroprusside that shows a reduction in pressure would conflict with clinical observations
in this population. Conversely, clinical data from patients with intracranial lesions that
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are administered nitroglycerin show a reduction in mean arterial pressure and cerebral
blood flow. These clinical observations are consistent with the computed results
presented herein.
Figures 19, 20 and 21 are comparative plots of the computed cerebrovascular
response to sodium nitroprusside, nitroglycerin and esmolol. Summarizing, the results of
the simulated cerebrovascular response to these agents indicate that esmolol should be
considered as the agent of choice during neurosurgery.

Figure 19: Effect of the administration of three antihypertensive agents on intracranial
pressure in a simulated patient with autoregulatory system intact and an initial mean
arterial pressure of 100 mm Hg.
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Figure 20: Effect of the administration of three antihypertensive agents on intracranial
pressure in a simulated patient with autoregulatory system impaired and an initial mean
arterial pressure of 100 mm Hg
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Figure 21: Effect of the administration of three antihypertensive agents on cerebral in a
simulated patient with autoregulatory system intact and an initial mean arterial pressure
of 100 mm Hg

CHAPTER 5
CONCLUSION AND RECOMMENDATIONS

5.1 Conclusion
The objective of this project was three-fold. The primary objective of this project was to
develop a computer model of cerebrovascular hemodynamics interacting with a
pharmacodynamic drug model to examine the effects of three commonly used antihypertensive agents upon intracranial pressure and cerebral blood flow. The second
objective was to utilize the model to predict patient response under different
physiological conditions. The final objective was to evaluate the computed intracranial
hemodynamic response to three agents and postulate the agent that will induce
hypotension with the least probability of untoward events.
The result of this research yielded following results and observations:
•

Three individual cerebrovascular models were developed that predicted

intracranial hemodynamic responses to the administration of three commonly
used anti-hypertensive agents that correlate with reported experimental data.
•

The computations predict that vasodilators such as sodium nitroprusside and

nitroglycerin dilate cerebral vascular vessels increasing cerebral blood volume
concomitantly increasing intracranial pressure.
•

The model predicts that in simulated patients with an impaired autoregulatory

system a reduction in mean arterial pressure does not significantly affect
intracranial pressure and cerebral blood flow.
•

The cerebrovascular model of intracranial hemodynamic response to the

administration of esmolol also demonstrated results that correlate with reported
45

46
experimental data. The model predicts that beta-adrenergic hypotensive agents do
not produce marked changes in intracranial pressure or cerebral blood flow.
• Esmolol effectively induces hypotension without significantly affecting
intracranial pressure or cerebral blood flow.
Based on a comparison of computed intracranial pressure and cerebral blood flow
response to two vasodilators and a beta-adrenergic agent, the author would recommend
the use of beta-adrenergic agents such as esmolol as a anti-hypertensive agent in patients
with autoregulatory system intact or non-autoregulated cerebral circulation and under
normal or elevated mean arterial pressure.

5.2 Recommendations
Concern regarding the sodium nitroprusside toxicity has prompted anesthesiologists to
supplement sodium nitroprusside infusion with beta-adrenergic receptor blockers,
calcium channel blockers, and nitroglycerin. The model described herein was used to
predict cerebrovascular response to the effects of sodium nitroprusside without
supplemental administration. The results demonstrated that direct dilation of cerebral
vessels increased cerebral blood volume and concomitantly increased intracranial
pressure. The sodium nitroprusside model may be extended to combine multiple
pharmacodynamic relationships to model concurrent administrations of multiple agents.
In addition, hypertension has been reported to spike upon discontinuing administration of
sodium nitroprusside [17]. Using experimental data a pharmacodynamic relationship
may be developed to predict this phenomenon
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In addition, presence of mass lesions proximal to the descending veins may cause
a blockage to cerebral blood flow out of the compartment. Therefore, the presence of
lesion proximal to the descending veins may contraindicate the administration of
vasodilators. The intracranial hemodynamic sub-model may be extended to simulate a
blockage within this compartment to predict the affects of vasodilators in the presence of
mass lesions. An additional sub-model representing the presence of mass legions may be
added to the overall model structure. The mass lesion sub-model may be an exponential
relationship between mass lesion volume and resistance to extracranial outflow, R vsce..
The presence of a mass lesion would than increase resistance to extracranial venous
outflow thus reducing cerebral blood flow out of the compartment and increasing
intracranial pressure.

APPENDIX A
EQUATIONS

The cerebrovascular hemodynamic model equations presented below were programmed in Vissim
language to simulate patient cerebrovascular response during anti-hypertensive agent administration.
The Vissim block diagrams are provided in this appendix. Reference Table 1 for system parameters
and table 2 for definition of system symbols.
The cerebrovascular hemodynamic model equations were derived using the following
assumptions:
•

The change in fluid in a compartment is equal to the sum of the net fluid influx through the
compartmental boundaries, plus external sources.

■ The change in volume is produced by the changes in pressure difference.
•

Arteriolar-capillary and venous cerebrovascular resistance is controlled by chemical factors
including pharmacological agents.

•

The sum of all volumes does not change in time, i.e., constant volume.

■ Arterial-arteriolar and venous cerebrovascular resistance is a function of transmural pressure.

Constancy of the overall intracranial volume:
The constancy of the overall intracranial volume is defined as a function of the net fluxes
between the arterial-arteriolar, capillary, veins, venous sinus and cerebral tissue compartment
and additional volume added to the compartment.

Cic dPic/dt = Cai (dPa ,/ dt - dPic/dt) + Gf (Pc - P ic ) + Cvi (dPv/ dt - dPic/dt) - Go(Pic - Pvs) + I (13)
Intracranial pressure is derived by rearranging the equation and solving for intracranial pressure
as a function of time.
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dP ic/dt = [Gf (Pc - Pic ) + C v i (dPv/ dt) - Go (Pic - Pvs ) + II]

[Cai + Cvi + Cic]

(14)

Cerebral Arterial-arteriolar Compartment:
Cerebral Blood Flow is defined as the net fluxes between the arterial-arteriolar, capillary bed,

and cerebral tissue compartments.
Q = P a * R = Cai (dPa / dt - dPic/d t) + G ai(Pa - Pc)

(15)

Rearranging the equation and solving for arterial-arteriolar pressure yields the following
equation:

Par = [Gai Pa - GarPc]

l [Gai + Ga]

(16)

Capillary Compartment:
The volume of the capillary compartment is a function of the net fluxes between the

arterial-arteriolar, capillary and veins compartments:

Ga (Pa - Pv) - Gpv(Pc - Pv ) = Gf (Pc - Pic )

(17)

Rearranging the equation and solving for pressure of the capillary yields the following:
Pc = [GaPa + G pvPv + GfPv] / [Ga + Gpv + Gf]

(18)

Cerebral venous compartment:
The following equation defines the volume of the cerebral vein compartment as a function
of cerebral tissue compartment, capillary compartment and the venous sinus compartment:

Gpv(Pc - Pv) - Gvs(P v - P vs ) = Cvi(dPv/ dt - dPic/dt) (19)
Solving for the vein compartment pressure yields the following equation:
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Venous sinus compartment:

The following equation defines the volume of the venous sinus compartment as a function
of cerebral tissue compartment, veins compartment and the central venous compartment:

Gvs (Pv-Pvs ) + Go (Pic - Pvs ) = G ve (P vs - Pcv ) + Cve dP vs /dt

(21)

Solving for the venous sinus pressure yields the following equation:
dP vs/dt = [G vs (Pv —Pvs ) + Go (Pic - Pvs)-

G ve (Pvs - Pcv )]

Cve

(22)

Compliance equations of the arterial, venous and cerebral tissue compartments:

The derivation of the following compliance equations are described in detail in Section 2.2.
Ca = dVa /d( P a - Pic) = 1/ Ka( Pa - Pic)

(23)

Ca = dVa / d( Pa — Pic) = 1/ Ka( Pa-Pic-Pvi)

(24)

Cic = 1 / [Ke*(Pic+(Pic/ ic)2]

(25)
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Table 1: Parameter values used during the simulation

G ai = 2.77 cm3 sec-1 mm Hg-1
Gf = 0.42 * 10 cm 3 sec-1 mm Hg
Gvi= 2.77 cm 3 sec-1 mm Hg-1
Gai= 0.37 cm 3 sec -1 mm Hg -1
Cve = 2.34 cm mm Hg
Pvi= -2.5 mm Hg
Pa = 100 mm Hg

Gpv = 1.136 cm 3 sec -1 mm Hg-1
Go = 1.90 *10 cm 3 sec -1 mm Hg
G ve = 6.25 cm 3 sec -1 mm Hg -1
Ka = 3.68 cm 3
Ke = 0.26 cm 3
Kv = 0.31 cm 3

Table 2: Description of Symbols

Pa: Arterial pressure
Pc:Cerebral capillary pressure
Pv: Cerebral venous pressure
Pic:Intracranial pressure
Pvs:Venous sinus pressure
Pcv:Central venous pressure
Gai: Arterial-arteriolar conductance
Gpv:Proximal venous conductance
Gvs :Terminal venous conductance
Gve: Extracranial venous conductance
Gf:Conductance to CSF formation
Go:Conductance to CSF outflow
Cai:Intracranial arterial compliance
Cvi: Intracranial venous compliance
Cic:

Intracranial compliance

Cve:

Extracranial venous compliance

Q:Cerebral blood flow
Ka:Arterial elastance coefficient
Kv:Venous elastance coefficient
I:

Rate of liquid injection into subarachnoid space

APPENDIX B

CEREBROVASCULAR SYSTEM MODEL
The appendix contains a listing of the VisSim ® code for the Cerebrovascular System
Model developed.

Figure 22 Intracranial hemodynamic compound block with outputs
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Figure 23 Intracranial hemodynamic compound block expanded
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Figure 24 Pressure equations compound block expanded
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Figure 25 Pv cerebral venous pressure compound block expanded
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Figure 27 Pvs venous sinus pressure compound block expanded
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Figure 28 Pc cerebral capillary pressure compound block expanded
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Figure 32 Compliance equations compound block expanded
Pa

Figure 33 Cai arteriolar compliance compound block expanded
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Figure 35 Cvi intracranial venous compliance compound block expanded
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